LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

Search

ADMA Biologics Inc

Geschlossen

Branche Gesundheitswesen

13.15 0.54

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

12.92

Max

13.33

Schlüsselkennzahlen

By Trading Economics

Einkommen

35M

18M

Verkäufe

8M

82M

EPS

0.08

Gewinnspanne

21.748

Angestellte

624

EBITDA

7.9M

24M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

-9.79 downside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Aug. 2024

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

450M

3.1B

Vorheriger Eröffnungskurs

12.61

Vorheriger Schlusskurs

13.15

Nachrichtenstimmung

By Acuity

50%

50%

123 / 369 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

ADMA Biologics Inc Chart

Ähnliche Nachrichten

25. Juli 2024, 20:16 UTC

Ergebnisse

Norfolk Southern Grows 2Q Profit, Seeks to Leave Behind Derailment Tailwinds

25. Juli 2024, 22:57 UTC

Ergebnisse

Minas Buenaventura 2Q Net $74.4M >BVN

25. Juli 2024, 22:10 UTC

Ergebnisse

Berkshire Is Quickly Cutting Its Stake in Bank of America. More Sales Could Be Coming. -- Barrons.com

25. Juli 2024, 21:59 UTC

Market Talk
Ergebnisse

Global Energy Roundup: Market Talk

25. Juli 2024, 21:59 UTC

Market Talk
Ergebnisse

Norfolk Southern Lowers Operating Ratio in 2Q, Shares Jump -- Market Talk

25. Juli 2024, 21:51 UTC

Ergebnisse

Update: Berkshire Is Quickly Cutting Its Stake in Bank of America. More Sales Could Be Coming. -- Barrons.com

25. Juli 2024, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

Noble: Special Meeting of Diamond Stockholders to Vote on Transaction Is Currently Scheduled for Aug 27 >NE

25. Juli 2024, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

Noble Corp and Diamond Offshore: Announce Expiration of Hart-Scott-Rodino Act Waiting Period and Provide Transaction Update

25. Juli 2024, 21:18 UTC

Ergebnisse

A.J. Gallagher Earnings Show Insurance Brokers Are Anything but Humdrum -- Barrons.com

25. Juli 2024, 21:11 UTC

Top News

OpenAI Is Launching Search Engine, Taking Direct Aim at Google -- 2nd Update

25. Juli 2024, 21:10 UTC

Ergebnisse

Berkshire Is Quickly Cutting Its Stake in Bank of America. More Sales Could Be Coming. -- Barrons.com

25. Juli 2024, 21:02 UTC

Ergebnisse

Eldorado Gold: We Remain on Track to Achieve 2024 Guidance >ELD.T

25. Juli 2024, 21:01 UTC

Ergebnisse

Eldorado Gold 2Q Net $55.5M >EGO

25. Juli 2024, 21:01 UTC

Ergebnisse

Eldorado Gold 2Q Rev $297.1M >EGO

25. Juli 2024, 21:01 UTC

Ergebnisse

Eldorado Gold 2Q EPS 27c >EGO

25. Juli 2024, 21:01 UTC

Ergebnisse

Eldorado Gold 2Q Adj EPS 33c >EGO

25. Juli 2024, 20:56 UTC

Ergebnisse

Auto Stocks Were Crushed. Everything Is Fine. Really. -- Barrons.com

25. Juli 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

25. Juli 2024, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

25. Juli 2024, 20:43 UTC

Top News

Dow Industrials Rise After Surprisingly Strong GDP Data -- WSJ

25. Juli 2024, 20:31 UTC

Ergebnisse

IBM Stock Gains As Earnings Beat Expectations, AI Bookings Jump -- IBD

25. Juli 2024, 20:30 UTC

Top News

3M Earnings Are Coming. Investors Want Growth. -- Barrons.com

25. Juli 2024, 20:01 UTC

Ergebnisse

Norfolk Southern 2Q Rev $3B >NSC

25. Juli 2024, 20:01 UTC

Ergebnisse

Norfolk Southern 2Q Adj EPS $3.06 >NSC

25. Juli 2024, 20:01 UTC

Ergebnisse

Norfolk Southern 2Q EPS $3.25 >NSC

25. Juli 2024, 20:01 UTC

Ergebnisse

Norfolk Southern 2Q Adj EPS $3.06 >NSC

25. Juli 2024, 20:01 UTC

Ergebnisse

Norfolk Southern 2Q Net $737M >NSC

25. Juli 2024, 20:01 UTC

Ergebnisse

Norfolk Southern Reaffirms FY Adj Operating Ratio Guidance of 66%

25. Juli 2024, 20:01 UTC

Ergebnisse

Norfolk Southern 2Q Adj Railway Operating Ratio 65.1%

25. Juli 2024, 20:01 UTC

Ergebnisse

Norfolk Southern 2Q Rev $3.04B >NSC

Peer-Vergleich

Kursveränderung

ADMA Biologics Inc Prognose

Kursziel

By TipRanks

-9.79% Nachteil

12-Monats-Prognose

Durchschnitt 12.25 USD  -9.79%

Hoch 15 USD

Tief 10 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für ADMA Biologics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

4

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

13.05 / 13.73Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

No Evidence

Langfristig

Weak Bullish Evidence

Stimmung

By Acuity

123 / 369 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über ADMA Biologics Inc

ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include ADMA BioManufacturing and Plasma Collection Centers. The Company’s ADMA BioManufacturing segment reflects its immune globulin manufacturing and development operations in Florida. The Plasma Collection Centers segment consists of approximately three plasma collection facilities. Its products include BIVIGAM, ASCENIV and Nabi-HB. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.